

<b>NHS Greater Glasgow and Clyde</b>	<b>Paper No. 24/87</b>
<b>Paper Title</b>	<b>Standing Committee Chair's Board Report</b>
<b>Meeting:</b>	<b>NHSGGC Board Meeting</b>
<b>Date of Meeting:</b>	<b>27 August 2024</b>
<b>Purpose of Paper:</b>	<b>For Assurance</b>
<b>Classification:</b>	<b>Board Official</b>
<b>Name of Reporting Committee:</b>	<b>Finance, Planning and Performance Committee</b>
<b>Date of Reporting Committee:</b>	<b>6 August 2024</b>
<b>Committee Chairperson:</b>	<b>Ms Margaret Kerr</b>

## 1. Purpose of Paper

**The purpose of this paper is to:** inform the NHS Board on key items of discussion at the NHSGGC Finance, Planning and Performance Committee.

## 2. Recommendation

The Board is asked to note the key items of discussion at the recent meeting of the Finance, Planning and Performance Committee on 6 August 2024 as set out below and seek further assurance as required.

## 3. Key Items of Discussion

### 3.1 Transformation of Specialist Neurosciences, OMFS and Spinal Injuries Services in the West of Scotland – Pre OBC – Economic Case

- The Committee received a paper for approval.
- An overview of the work that had been undertaken to identify a preferred option for the re-provision of the Institute of Neurological Sciences on the Queen Elizabeth University Hospital Campus was provided.
- The Committee received a short presentation setting out the work that had taken place to identify a preferred site option following approval of the Initial

## BOARD OFFICIAL

Agreement by the Scottish Government Capital Investment Group in March 2023.

- An overview of the project costs, High Level Revenue Impact and value for money were provided for each of the 4 options presented.
- Following appraisal, Single New Build was the preferred option. This option could deliver a new Acute facility quickly, without the need for decant accommodation and with minimal disruption to existing services.
- The Committee were content to approve the paper for submission to the NHSGGC Board.

### **3.2 Radionuclide Full Business Case**

- The Committee received a paper for approval.
- An overview of the work that had been carried out in relation to the relocation of the Radionuclide Dispensary Unit, currently based at the Western Infirmary Site, was provided.
- The Committee noted the preferred strategic solution and a detailed financial overview supporting the preferred option of relocating the Research and Development (RND) service to Gartnavel General Hospital was provided.
- The Committee noted that, if approved, construction would commence in October 2024, with completion expected in May 2026;
- The Committee noted the Capital Costs and noted that the change to the procurement route had resulted in a total project saving of approximately £2.5m.
- The Committee were content to approve the paper for submission to the NHSGGC Board.

### **3.3 Research and Innovation Strategy 2024-2029**

- The Committee received a paper for approval
- An update was provided on the five strategic objectives, priorities and actions for research and innovation.
- Inclusion was a key focus of the Strategy, ensuring the local population were represented.
- The key actions of the Strategy will be developed into an implementation plan, which will be monitored through the appropriate governance structures. This will be aided by the development of a comprehensive performance management framework during 2024.
- The Committee were content to approve the paper for submission to the NHSGGC Board.

### **3.4 Medium Term Plan**

- The Committee received a paper for assurance.
- The Committee received an update on the progress in delivering the 3 year NHSGGC Medium Term Plan 2023-2026.
- The Committee recognised the significant progress made relating to the key deliverables.
- The Committee were content to note the update

### **3.5 Delivery Plan – Quarter 1 Summary Report**

- The Committee received a paper for assurance.
- The Committee received an update on the progress implementing the actions associated with the NHSGGC Delivery Plan 24/25.
- The Committee were content to note the update.

### **3.6 Financial Monitoring Report – Month 3**

- The Committee received a paper for assurance.
- At the 30<sup>th</sup> June 2024, the Board's financial ledger highlighted an overspend of £34.91m, of which £23.40m is attributed to unachieved savings and a pay and non-pay overspend.
- The Committee received an update on the key cost pressure areas, Sustainability and Value and Capital Expenditure.
- The Committee noted the overall financial challenge for the Board, noting that there was no change to the forecast deficit based on the Month 3 position.
- The Committee were content to note the update.

### **3.7 Performance Report Month**

- The Committee received a paper for assurance.
- The Committee noted key areas of improvement which included CAMHS and Psychological Therapies performance, the quarterly position for alcohol and drugs remained positive and patients accessing Podiatry Services in under 4 weeks continued to exceed the national target
- The Committee noted areas of improvement which included MSK Physiotherapy waiting times, Delayed Discharges and Mental Health delays.
- The Committee were content to note the update.

## **4. Issues for referral to other Standing Committees or escalation to the NHS Board**

There were no issues for referral to other Standing Committees or escalation to the NHS Board.

## **5. Date of Next Meeting**

The next meeting of the Finance, Planning and Performance Committee will take place on Tuesday, 8 October 2024.